(Frederick) Swinford Edwards, a demonstrator in anatomy and surgery

at St. Bartholomew’s. Unfortunately, the specimen could not be located and is presumed lost. To establish this specimen as the first known example of a joint-related intraneural cyst, we completed a review of >400 other cases and confirmed this statement. The first observation of an articular origin for an intraneural cyst, made by 2 eminent surgeons, has not been properly acknowledged. Considered with a modern perspective, this historical case solidifies the articular (synovial) origin for these unusual intraneural cysts, a finding that has important treatment implications.”
“Untreated de novo (n=421) and secondary (n=189) acute myeloid leukemia (AML) patients >= 60 years received intensified chemotherapy, including daunorubicin Selleckchem GW786034 60 mg/m(2) and etoposide 100 mg/m(2) selleck inhibitor during days 1, 2, 3 with cytarabine 100 mg/m(2) during days 1-7, with a second induction if needed and one consolidation course with these drugs and doses for 2, 2 and 5 days, respectively. In all, 287 (47%) achieved complete remission (CR), 136 (22%) died and 187 (31%) were non-responders. CR rates were 27, 44 and 52% for complex karyotypes, rare aberrations and neither (P<0.001), 52 and 37% for de novo and secondary AML (P=0.003), and 53 and 42% for age 60-69 and >=

70 years (P=0.015). In multivariable analysis, CR predictors included non-complex/non-rare

selleck chemical karyo-types (P<0.001), de novo AML (P<0.001), better performance status (PS) (P<0.001) and younger age (P=0.001). Disease-free (DFS) and overall (OS) survival medians were 6.8 (95% CI: 6.2, 7.8) and 7.2 (95% CI: 6.4, 8.6) months. In multivariable analysis, DFS was shorter for complex karyotypes (P<0.001) and increasing white blood count (WBC) (P<0.001) and age (P=0.038), and OS for complex karyotypes (P<0.001), increasing WBC (P=0.001) and age (P<0.001), poorer PS (P<0.001) and secondary AML (P=0.010). Outcomes and prognostic factors were similar to those in previous Cancer and Leukemia Group B studies. Leukemia (2011) 25, 800-807; doi: 10.1038/leu.2011.9; published online 15 February 2011″
“BACKGROUND: Introduction of the portable intraoperative CT scanner provides for a precise and cost-effective way of fusing head CT images with high-tesla MRI for the exquisite definition of soft tissue needed for stereotactic targeting.

OBJECTIVE: To evaluate the accuracy of stereotactic electrode placement in patients undergoing deep brain stimulation (DBS) by comparing frame-based postimplantation intraoperative CT (iCT) images fused to a recent 3T-MRI with frame-based post-implantation intraoperative MRI (iMRI) alone.